Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States

References

• National Cancer Institute (NCI) Surveillance Epidemiology and End Results Program (SEER). Primary mediastinal (thymic) large B-cell lymphoma 2019. [cited 2019 June 18]. Available from: https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5318/.
   Google Scholar
• Jaffe E, Harris N, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 3. Lyon, France: World Health Organization Press; 2001.
   Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–2669.
   PubMed Web of Science ®Google Scholar
• Liu PP, Wang KF, Xia Y, et al. Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis. Medicine (Baltimore). 2016;95(27):e4054.
   PubMed Web of Science ®Google Scholar
• © National Comprehensive Cancer Network Inc. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.32019. All rights reserved. 2019 [cited February 13, 2020]. Available from: to view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011; Mar22(3):664–670.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica. 2001;86(2):187–191.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123–130.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258–1264.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Janik J, et al. Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation. Blood. 2005;106(11):929–929.
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15(4):1646–1653.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94(10):3289–3293.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329–1336.
   PubMed Web of Science ®Google Scholar
• Tomassetti S, Chen R, Dandapani S. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol. 2019;10:2040620719841591.
   Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998;91(2):717–723.
   PubMed Web of Science ®Google Scholar
• Poire X, van Besien K. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol. 2009;2(1):31–36.
   PubMed Web of Science ®Google Scholar
• Zinzani PL. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large b-cell lymphoma: efficacy and safety from the phase 2 CheckMate 436 study. 15th International Conference on Malignant Lymphoma; June 18-22, 2019; Lugano, Switzerland 2019.
   Google Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014;19(9):901–908.
   PubMed Web of Science ®Google Scholar
• Ramsey S, Henk H, Smith G, et al. First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database. Lung Cancer Management. 2015;4(3):131–143.
   Web of Science ®Google Scholar
• Seal BS, Sullivan SD, Ramsey S, et al. Medical costs associated with use of systemic therapy in adults with colorectal cancer. J Manag Care Pharm. 2013;19(6):461–467.
   PubMed Web of Science ®Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693.
   PubMed Web of Science ®Google Scholar
• Optum I. Clinformatics^® Data Mart User Manual. 2018;1–41.
   Google Scholar
• Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–144.
   PubMed Web of Science ®Google Scholar
• Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534–544.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grant C, Dunleavy K. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369(3):283–284.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol. 1990;8(5):804–808.
   PubMed Web of Science ®Google Scholar
• Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993;11(7):1336–1343.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130(5):691–699.
   PubMed Web of Science ®Google Scholar
• Haioun C, Gaulard P, Roudot-Thoraval F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol. 1989;12(5):425–429.
   PubMed Web of Science ®Google Scholar
• YESCARTA® (axicabtagene ciloleucel) highlights of prescribing information. Kite Pharma, Inc.; 2019.
   Google Scholar
• Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–327.
   PubMed Web of Science ®Google Scholar